You might like
$PRTG data is coming, it's a great time to invest!
$PRTG Unlike other biotechs portage have designed import-201 trial to meet the exact clinical requirements $BMS & $MRK require. It helps when the chairman worked at BMS / brought nivolumab to market! ir.portagebiotech.com/news-releases/…
$PRTG
$PRTG Boom! Global trial site updated with June 5th start. This is running in parallel with the going p1/p2 uk arm of the trial. Data is coming ! And quick with 12 new trial locations in the US and spain. Merck collab is really kicking into action now $MRK
$PRTG second solely owned asset about to land in the clinic. Big milestone to derisk the pipeline
Join us on March 9th at 10:30 AM ET for a virtual KOL event with @PortageBiotech, featuring Dr. Lawrence Fong and Dr. Sumit Subudhi, discussing targeting adenosine for the treatment of cancer. Register here: lifesci.events/PortageReg #adenosine #ImmunoOncology $PRTG
$PRTG @PortageBiotech’s Adenosine, A2Bs, entering trial any day now. Good KOL to sign up for. Also, new trial on IMM60 and PEM, clinicaltrials.gov/ct2/show/NCT05… Lots finally moving with this one.
$PRTG second solely owned asset about to land in the clinic. Big milestone to derisk the pipeline
Timely additions to the presentation ahead of JPM next week. -highlighting combo date with PEM (Merck collab) this year. - partnering opportunities and previous high value exits , Biohaven as example. Chart is looking primed and fundamentals. Going to be some year $PRTG
@IntensityInc $PRTG @PortageBiotech @Merck Seems newsworthy…biospace.com/article/releas… 1/
Part 3: Notes from an investor. $PRTG @PortageBiotech @Merck @bmsnews @IntensityInc On Friday $PRTG tweeted info on its adenosine portfolio. If you recall from Part 1 in my thread, @portagebiotech has a pipeline of 14 assets with 7 clinical trials ongoing. The adenosine 1/
$PRTG @PortageBiotech @Merck @bmsnews So @IntensityInc presented clinical data mid November at SITC titled “Safety and Survival Results From a Phase 1/2 Trial of Intratumoral Agent INT230-6 (cisplatin vinblastine) Induces Immunological Cancer Cell Death Alone or…1/
Our collaborator @IntensityInc is presenting their work at @SABCSSanAntonio this week. The presentation will demonstrate a novel approach of locally killing a tumor, showcasing a major advance in the treatment of immunologically cold tumors: bit.ly/3VcVlLr #SABCS22
instead of getting there with 100 employees and an expensive office in the Massachusetts biotech corridor, we do it with 10 senior people working virtually. If you look at our burn rate, it is substantially lower than the rate you see in other biotech firms.” 6/
$PRTG the no1 small bio blockbuster play Read this interview by Ian Walters, CEO - new drug development model - connected ex $BMS board - multiple clincal assets - early big pharma engagement $MRK $BMS $XBI clinicalleader.com/doc/portage-bi…
We’re excited to announce our #clinicaltrial agreement with @Merck to explore the complementary mechanism of our #iNKT agonist with #Keytruda & how it can enhance long-term benefits for people with non-small cell #lungcancer & melanoma. Full release here: bit.ly/3DJEKHy
Portage CEO Ian Walters presented progress on our #iNKT agonist, PORT-2, at #ASCO22, the only presentation focused on the potential of this key class of #immune cell at the conference. Registrants can view our abstract and poster here: bit.ly/3NC3yVF @ASCO
Nice mention of Portages lead asset IMM60 being picked up as a ground breaking combo study. $PRTG futurebridge.com/asco20/
Imagine a drug which can activate all these pathways whilst directly attacking the tumor Portage have this ! Nkarta(NK cell) closest compsrable released prelim data 60%CR RATE! PORT-2 recruits B ,T, dendritic & Nk cells ! Full immunological response! $PRTG #ASCO22 $NKTX #iNKT
$PRTG
In #immunotherapy research, we are seeing an increase in validation of targeting the innate #ImmuneSystem. Portage's #iNKT agonists are designed to stimulate both innate and adaptive immunity to attack and kill cancer cells. See more here: bit.ly/3i66QTf #IansInsight
In #immunotherapy research, we are seeing an increase in validation of targeting the innate #ImmuneSystem. Portage's #iNKT agonists are designed to stimulate both innate and adaptive immunity to attack and kill cancer cells. See more here: bit.ly/3i66QTf #IansInsight
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity globenewswire.com/news-release/2… $PRTG
Hi Ben Really interesting article Have you checked Portage Biotech out who in the true sense have developed an inkt agonist Full dose escalation not far behind $NKTX, inital safety in March 22 -no AE'S. Combo cohort with Keytruda in progress and mono high dosing . $PRTG #inkt
Today we are highlighting promising data on our #STING activating #immunotherapy, PORT-5, in collaboration with @StimunityBio at the @AACR 2022 Annual Meeting. Data will be shared in a presentation today at 9:00 a.m. CT. Learn more here: bit.ly/3LY5LK0 $PRTG #AACR22
Today we announced updates on our #ClinicalDevelopment programs and strategic goals for the remainder of 2022. We look forward to advancing in the clinic, expanding our pipeline & establishing new collaborations. Read full release here: bit.ly/3Dr3bch $PRTG
United States Trends
- 1. Luigi Mangione N/A
- 2. #ICEoffOurStreets N/A
- 3. Hugh Morris N/A
- 4. Tomodachi Life N/A
- 5. Senator Grassley N/A
- 6. Nintendo N/A
- 7. Mark Anderson N/A
- 8. Pepsi N/A
- 9. Sonya Massey N/A
- 10. Dignity N/A
- 11. SpaceX N/A
- 12. Joseph Quinn N/A
- 13. USA 250 N/A
- 14. Carter Bryant N/A
- 15. Miis N/A
- 16. Aranofsky N/A
- 17. $CANCER N/A
- 18. Fulton County N/A
- 19. Cigarettes N/A
- 20. Lowe N/A
Something went wrong.
Something went wrong.